PG
SIOX

PEAK6 Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

PEAK6 Group’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,500
Closed -$155K – 5428
2015
Q3 		$155K Buy
+1,500
New +$176K ﹤0.01% 3963

Other funds holding SIOX

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PEAK6 Group's SIOX Position: Q4 2015 in Review

PEAK6 Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2015, closing a stake of 488 shares — an estimated $50K sold.

PEAK6 Group first reported a position in SIOX in Q3 2015 and held it in 1 quarter. The position peaked at $50K in Q3 2015. 70 funds tracked by Wall St. Rank hold SIOX as of Q4 2015.

  • PEAK6 Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 488 Sio Gene Therapies Inc. Common Stock shares in Q4 2015, an estimated $50K.
  • PEAK6 Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • PEAK6 Group's Sio Gene Therapies Inc. Common Stock position peaked at $50K in Q3 2015.
  • 70 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.